VivoSeq
Other

Pain Control

0

Pipeline Programs

17

Active Trials

2

Companies Involved

Pain Control is an early-stage landscape with 0 programs across 2 companies. The most active players are Cumberland Pharmaceuticals, Xgene Pharmaceutical Group.

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

9/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

82

clinical trials

Completed49 · 60%
Recruiting10 · 12%
Unknown status9 · 11%
Not yet recruiting5 · 6%
Terminated4 · 5%
Withdrawn3 · 4%
Other2 · 2%

Trial Activity

82 trials

Pain Control for Undergoing Costal Cartilage Harvesting
Recruiting·MMayo Clinic·Phase 4·NCT05285566·60 enrolled
Comparing Perioperative Outcomes in Pain Control
Active, not recruiting·UUniversity of California, San Diego·Phase 4·NCT05690282·100 enrolled
Evaluating Suzetrigine for Pain Control Following TKA
Not yet recruiting·AAdventHealth·Phase 3·NCT07357376·210 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)